title: Phase II evaluation of oral idarubicin (4-demethoxydaunorubicin) in patients with disseminated malignant melanoma.
authors.forename: M
authors.initials: M
authors.lastname: Lopez
authors.forename: L
authors.initials: L
authors.lastname: Di Lauro
authors.forename: P
authors.initials: P
authors.lastname: Papaldo
authors.forename: F
authors.initials: F
authors.lastname: Ganzina
authors.forename: N
authors.initials: N
authors.lastname: Di Pietro
authors.forename: B
authors.initials: B
authors.lastname: Lazzaro
mesh_terms: D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D003630:Daunorubicin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004341:Drug Evaluation; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D015255:Idarubicin; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009362:Neoplasm Metastasis; D012878:Skin Neoplasms / Q000188:drug therapy*
chemical_list: D000903:Antibiotics, Antineoplastic; D015255:Idarubicin; D003630:Daunorubicin